Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide in high-risk myeloid disease with del(5q)/monosomy 5
2007-000450-31Phase 2Completed
- Sponsor
- Nordic MDS Group
- Start
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), sponsored by Nordic MDS Group. Primary endpoint: Major cytogenetic response at 16 weeks. Started Jun 2007; status: completed.
02
Drugs
lenalidomide
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2007-000450-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000450-31.